Close Menu
  • Home
  • Economic News
  • Stock Market
  • Real Estate
  • Crypto
  • Investment
  • Personal Finance
  • Retirement
  • Banking

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

What's Hot

Looking for an income stream for decades? Here’s how to emulate the Bobby Bonilla plan to get paid over time

July 1, 2025

What’s next for the ‘big, beautiful bill’?

July 1, 2025

The Bond Canary In The “Big Beautiful” Coal Mine

July 1, 2025
Facebook X (Twitter) Instagram
  • Contact Us
  • Privacy Policy
  • Terms Of Service
Tuesday, July 1
Doorpickers
Facebook X (Twitter) Instagram
  • Home
  • Economic News
  • Stock Market
  • Real Estate
  • Crypto
  • Investment
  • Personal Finance
  • Retirement
  • Banking
Doorpickers
Home»Stock Market»US FDA puts Kezar Life Sciences’ lupus treatment trial on hold after patient deaths By Reuters
Stock Market

US FDA puts Kezar Life Sciences’ lupus treatment trial on hold after patient deaths By Reuters

October 11, 2024No Comments1 Min Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

(Reuters) – The U.S. Food and Drug Administration has issued a clinical hold on Kezar Life Sciences (NASDAQ:)’ trial of an experimental drug for lupus, the company announced on Friday.

This decision follows Kezar’s voluntary pause of the mid-stage trial of the drug, zetomipzomib, in order to review safety data in response to the deaths of four patients participating in the trial in the Philippines and Argentina.

The drug was being evaluated by Kezar in patients with active lupus nephritis, a condition that leads to inflammation and kidney damage due to the autoimmune disease lupus.

© Reuters. FILE PHOTO: FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo

An independent study committee recommended the trial pause after identifying a common pattern of symptoms in three of the fatal cases, with the deaths occurring shortly after dosing. Additionally, a non-fatal adverse event showed a similar temporal relationship to dosing.

Kezar stated that a separate mid-stage trial evaluating zetomipzomib in patients with autoimmune hepatitis is ongoing, with no serious adverse events reported thus far.

deaths FDA hold Kezar Life lupus patient puts Reuters Sciences Treatment trial
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

Variable Universal Life Insurance (VUL): What You Need to Know

June 29, 2025

Judge sets trial timeline for Mutual of Omaha and Longbridge

June 12, 2025

Senior Federal Reserve official puts ‘50-50’ odds on tariffs sparking sustained US inflation

June 6, 2025
Add A Comment
Leave A Reply Cancel Reply

Top Posts

Why corporate top brass defy neat investment models

August 29, 20241 Views

Chromia Introduces Filehub for Secure and Scalable Data Storage

October 16, 20240 Views

Michigan Real Estate Commissions: What to Expect in 2024

September 30, 20240 Views
Stay In Touch
  • Facebook
  • YouTube
  • TikTok
  • WhatsApp
  • Twitter
  • Instagram
Latest
Retirement

Looking for an income stream for decades? Here’s how to emulate the Bobby Bonilla plan to get paid over time

July 1, 20250
Economic News

What’s next for the ‘big, beautiful bill’?

July 1, 20250
Economic News

The Bond Canary In The “Big Beautiful” Coal Mine

July 1, 20250
Facebook X (Twitter) Instagram Pinterest
  • Contact Us
  • Privacy Policy
  • Terms Of Service
© 2025 doorpickers.com - All rights reserved

Type above and press Enter to search. Press Esc to cancel.